Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) antibody

Details for Product No. ABIN393540
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms PDJ, PRKN, AR-JP, LPRS2, pdr-1, CG10523, Dmel\\CG10523, Dpark, SD01679, dpk, si:ch211-123f21.1, zgc:112390, LOC100150461
(39), (12), (12), (6), (5)
(35), (4), (2)
Clonality (Clone)
Monoclonal ()
(2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2)
Immunofluorescence (IF), Western Blotting (WB)
(22), (20), (10), (9), (5), (5), (2), (2), (1)
Pubmed 5 references available
Catalog no. ABIN393540
Quantity 0.1 mg
450.00 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen PARK2 (AAH22014, 288 a.a. ~ 388 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K
Clone 1H4
Isotype IgG3 kappa
Specificity PARK2 (AAH22014, 288 a.a. ~ 388 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Purification This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Alternative Name PARK2
Background Synonyms: Serine protease inhibitor J6, 47 kDa heat shock protein, Collagen-binding protein, Colligin, Serpin H1,Hsp47, Cbp1, Serpinh1
Molecular Weight 51641 DA
Gene ID 12406
Research Area Ubiquitin-related antibodies, Protein Modifications, Cell Structure
Application Notes Western blot = 1:500-1000

Background: The precise function of this gene is unknown, however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support.

Restrictions For Research Use only
Concentration 0.25mg/ml
Buffer PBS with 0.09% (w/v) sodium azide.
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Supplier Images
anti-Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) antibody Immunofluorescence of monoclonal antibody to PARK2 on HeLa cell (antibody concentration 10 µg/mL). PARK2 monoclonal antibody (M01), clone 1H4 Western Blot analysis of PARK2 expression in Jurkat.
anti-Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) antibody (2) anti-Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) antibody (Image 2)
Background publications Suen, Narendra, Tanaka et al.: "Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Issue 26, pp. 11835-40, 2010 (PubMed).

Marder, Tang, Mejia-Santana et al.: "Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study." in: Archives of neurology, Vol. 67, Issue 6, pp. 731-8, 2010 (PubMed).

Prabhakar, Vinish, Das et al.: "Occurrence of PARK2 mutations in a never-smoker population with Parkinson's disease in North India." in: Neuroepidemiology, Vol. 35, Issue 2, pp. 152-9, 2010 (PubMed).

Bailey, Xie, Do et al.: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).

Kägi, Klein, Wood et al.: "Nonmotor symptoms in Parkin gene-related parkinsonism." in: Movement disorders : official journal of the Movement Disorder Society, Vol. 25, Issue 9, pp. 1279-84, 2010 (PubMed).

Hosts (35), (4), (2)
Reactivities (39), (12), (12), (6), (5)
Applications (22), (20), (10), (9), (5), (5), (2), (2), (1)
Conjugates (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2)
Epitopes (12), (12), (1), (1), (1)
back to top